Epigenetic control in pituitary tumors

Endocrine Journal

Volumn 55, Issue 6, 2008, Pages 951-957

  Ezzat, Shereen ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Epigenetic control; FGFR2; MAGE; Pituitary tumors

Indexed keywords

ESTROGEN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HISTONE; KERATINOCYTE GROWTH FACTOR; MELANOMA ANTIGEN 3; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOBLASTOMA PROTEIN;

ACETYLATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CPG ISLAND; DEACETYLATION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE CONTROL; GENE SILENCING; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION INITIATION;

ANIMALS; ANTIGENS, NEOPLASM; DNA METHYLATION; EPIGENESIS, GENETIC; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MODELS, BIOLOGICAL; PITUITARY NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 58549085590     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-082     Document Type: Review

References (55)

1. Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19: 798-827.
2. Asa SL, Ezzat S (2002) The pathogenesis of pituitary tumours. Nat Rev Cancer 2(11): 836-849.
3. Treier M, Gleiberman AS, O'Connell SM, et al. (1998) Multistep signaling requirements for pituitary organogenesis in vivo. Genes Dev 12(11): 1691-1704.
4. Paez-Pereda M, Giacomini D, Refojo D, et al. (2003) Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 100(3): 1034-1039.
5. Itoh N, Ornitz DM (2004) Evolution of the Fgf and Fgfr gene families. Trends Genet 20(11): 563-569.
6. Ornitz DM, Zu J, Colvin JS, et al. (1996) Receptor specificity of the fibroblast growth factor family. J Biol Chem 271: 15292-15297.
7. Luo Y, Ye S, Kan M, McKeehan WL (2006) Structural specificity in a FGF7-affinity purified heparin octasaccharide required for formation of a complex with FGF7 and FGFR2IIIb. J Cell Biochem 97(6): 1241-1258.
8. Thisse B, Thisse C, Weston JA (1995) Novel FGF receptor (Z-FGFR4) is dynamically expressed in mesoderm and neurectoderm during early zebrafish embryogenesis. Dev Dyn (203): 377-391.
9. Thisse B, Thisse C (2005) Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol 287(2): 390-402.
10. Baraniak AP, Lasda EL, Wagner EJ, Garcia-Blanco MA (2003) A stem structure in fibroblast growth factor receptor 2 transcripts mediates cell-type-specific splicing by approximating intronic control elements. Mol Cell Biol 23(24): 9327-9337.
11. De Moerlooze L, Spencer-Dene B, Revest J, Hajihosseini M, Rosewell I, Dickson C (2000) An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Develop 127(3): 483-492.
12. Celli G, LaRochelle WJ, Mackem S, Sharp R, Merlino G (1998) Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J 17(6): 1642-1655.
13. Ezzat S, Smyth HS, Ramyar L, Asa SL (1995) Heterogeneous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 80: 878-884.
14. Asa SL, Ramyar L, Murphy PR, Li AW, Ezzat S (2001) The endogenous fibroblast growth factor-2 antisense gene product regulates pituitary cell growth and hormone production. Mol Endocrinol 15(4): 589-599.
15. Abbass SAA, Asa SL, Ezzat S (1997) Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab 82: 1160-1166.
16. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL (2002) Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109(1): 69-78.
17. Ezzat S, Yu S, Asa SL (2003) Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5′ fibroblast growth factor receptor-4 promoter. Am J Pathol 163(3): 1177-1184.
18. Yu S, Asa SL, Weigel RJ, Ezzat S (2003) Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. J Biol Chem 78(22): 19597-19602.
19. Ezzat S, Zheng L, Asa SL (2004) Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 18(10): 2543-2552.
20. Zhu X, Lee K, Asa SL, Ezzat S (2007) Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol 170(5): 1618-1628.
21. Alexander JM (2001) Tumor suppressor loss in pituitary tumors. Brain Pathol 11(3): 342-355.
22. Kondo T, Zhu X, Asa SL, Ezzat S (2007) The Cancer/Testis Antigen MAGE-A3/6 is a Novel Target of FGFR2-IIIb Through Histone H3 Modifications in Thyroid Cancer. Clinical Cancer Research 13: 4713-4720.
23. Asa SL. Tumors of the Pituitary Gland. Third Series [Fascicle 22]. 1998. Washington, D.C., Armed Forces Institute of Pathology. Atlas of Tumor Pathology. Rosai, J.
24. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Tumours of Endocrine Organs. 2004. Lyons, IARC. World Health Organization Classification of Tumours. Kleihues, P. 2004.
25. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW (2007) 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26(1): 77-90.
26. Ushijima T, Watanabe N, Okochi E, Kaneda A, Sugimura T, Miyamoto K (2003) Fidelity of the methylation pattern and its variation in the genome. Genome Res 13(5): 868-874.
27. Monte M, Simonatto M, Peche LY, et al. (2006) MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 103(30): 11160-11165.
28. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P (2002) Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 52(3): 245-252.
29. Ricol D, Cappellen D, El Marjou A, et al. (1999) Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 18(51): 7234-7243.
30. Bernard-Pierrot I, Ricol D, Cassidy A, et al. (2004) Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. Oncogene 23(57): 9201-9211.
31. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S (2007) Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 67(11): 5461-5470.
32. Zhang Y, Wang H, Toratani S, et al. (2001) Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci USA 98(20): 11336-11340.
33. Xiao J, Chen HS (2004) Biological functions of melanoma-associated antigens. World J Gastroenterol 10(13): 1849-1853.
34. van der BP, Traversari C, Chomez P, et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038): 1643-1647.
35. Weynants P, Lethe B, Brasseur F, Marchand M, Boon T (1994) Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer 56(6): 826-829.
36. Otte M, Zafrakas M, Riethdorf L, et al. (2001) MAGE-A gene expression pattern in primary breast cancer. Cancer Res 61(18): 6682-6687.
37. Kim J, Reber HA, Hines OJ, et al. (2006) The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer 118(9): 2269-2275.
38. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. (1996) p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 38: 765-771.
39. Sigalotti L, Fratta E, Coral S, et al. (2004) Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′- deoxycytidine. Cancer Res 64(24): 9167-9171.
40. Wischnewski F, Pantel K, Schwarzenbach H (2006) Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 4(5): 339-349.
41. Lloyd RV, Cano M, Landefeld TD (1988) The effects of estrogens on tumor growth and on prolactin and growth hormone mRNA expression in rat pituitary tissues. Am J Pathol 133: 397-406.
42. Ezzat S, Asa SL (2006) Mechanisms of disease: The pathogenesis of pituitary tumors. Nat Clin Pract Endocrinol Metab 2(4): 220-230.
43. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA (1992) Effects of an Rb mutation in the mouse. Nature 359: 295-300.
44. Woloschak M, Yu A, Xiao J, Post KD (1996) Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. Int J Cancer 67(1): 16-19.
45. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D (1995) Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 55: 1613-1616.
46. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE (2000) Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60(5): 1211-1216.
47. Bates AS, Farrell WE, Bicknell EJ, et al. (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82: 818-824.
48. Kip1 display increased body size,multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720.
49. Bamberger CM, Fehn M, Bamberger AM, et al. (1999) Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol 140(3): 250-255.
50. Lidhar K, Korbonits M, Jordan S, et al. (2002) Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 84(10): 3823-3830.
51. Zhang X, Sun H, Danila DC, et al. (2002) Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87(3): 1262-1267.
52. Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE (2004) Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 23(4): 936-944.
53. Qian ZR, Sano T, Yoshimoto K, et al. (2005) Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest 85(4): 464-473.
54. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A (2005) Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab 90(4): 2179-2186.
55. Yang B, O'Herrin S, Wu J, et al. (2007) Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol 127(2): 267-275.